Compare ATCH & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATCH | GBIO |
|---|---|---|
| Founded | 2022 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.2M | 36.3M |
| IPO Year | N/A | 2020 |
| Metric | ATCH | GBIO |
|---|---|---|
| Price | $0.25 | $5.70 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $8.88 |
| AVG Volume (30 Days) | ★ 4.2M | 65.6K |
| Earning Date | 02-18-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $12,303,120.00 | ★ $15,270,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 80.78 | N/A |
| 52 Week Low | $0.14 | $3.00 |
| 52 Week High | $15.27 | $12.40 |
| Indicator | ATCH | GBIO |
|---|---|---|
| Relative Strength Index (RSI) | 34.35 | 60.89 |
| Support Level | $0.25 | $5.40 |
| Resistance Level | $0.27 | $5.69 |
| Average True Range (ATR) | 0.02 | 0.22 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 0.89 | 87.72 |
AtlasClear Holdings Inc is a fintech company. Its goal is to build a cutting-edge technology-enabled financial services firm that would create a more efficient platform for trading, clearing, settlement, and banking of evolving and financial products with a focus on financial services firms. It is a fintech-driven business-to-business platform that expects to power innovation in fintech, investing, and trading. The company believes it is positioned to provide a modern, mission-critical suite of solutions to its clients, enabling them to reduce their transaction costs and compete more effectively in their businesses.
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.